Celegence Holdings LLC has made a significant strategic investment in Soterius, Inc., a provider of outsourced services, collaboration technologies, and data assets in the drug safety and medical affairs space. The investment – made through Soterius’ Series A financing round – has resulted in a partnership that brings synergies to both Celegence and Soterius. It enables both organizations to take advantage the knowledge and experience of their respective teams in order to expand reach and drive growth. Celegence, a Celegence Holdings LLC company, provides regulatory affairs services and technology to the life sciences industry to enable efficient and intelligent compliance with complex global and local regulatory requirements.
Celegence helps life sciences companies navigate complex global regulatory requirements by providing consulting services and solutions dedicated to regulatory affairs. Celegence supports life sciences customers in the areas of regulatory intelligence, RIMS, publishing, labelling, medical writing, and compliance with new regulations for different product portfolios. Celegence’s depth of experience and extensive delivery capability allows regulatory affairs teams to operate more efficiently, reduce cost, and improve compliance.
For more information, contact us online now or follow us on LinkedIn and Twitter.
Soterius is a trusted name in the life sciences industry for providing integrated outsourced drug safety and pharmacovigilance, medical affairs, and medical writing services with a customer base spanning Top 10 pharmaceutical companies, biopharmaceutical companies, global cosmetics conglomerates and generic drug manufacturers. Soterius supports life sciences companies through their drug development, approval, and commercialization processes, helping them find and deploy an optimal mix of outsourced and in-house operations. In addition to providing outsourced services, Soterius has several technology solutions and data assets that improve productivity, collaboration and compliance.
For more information, visit www.soterius.com or follow Soterius on LinkedIn and Twitter.